期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Bruton酪氨酸激酶在B细胞肿瘤中的研究进展 被引量：1

Research progress of Bruton tyrosine kinase in B cell malignances
原文传递
导出
摘要 Bruton酪氨酸激酶（Btk）是非受体蛋白酪氨酸激酶Tec家族的成员之一,在B淋巴细胞的生长、增殖、分化和信号转导中起重要作用.当B细胞受体（BCR）受到各种因素激活后,Btk将被磷酸化而激活,激活的Btk引起下游信号分子的活化,BCR信号通路的活化在B细胞肿瘤的发生和维持中起重要作用.文章就近年来Btk在B细胞肿瘤中的研究进展作一综述. Bruton tyrosine kinase （Btk） is a member of the non-receptor protein tyrosine kinases of Tec family.It plays an important role in growth,proliferation,differentiation and signal transduction of B lymphocyte.After activation of B-cell receptor （BCR） by diverse stimuli,Btk is activated through tyrosine phosphorylation.Activated Btk can stimulate several downstream signaling proteins.Btk and BCR signaling pathways play important roles in initiation and maintenance of B cell malignancies.This review focuses on the recent findings in association of Btk and B cell malignancies.
作者 邓媛 张欣 于亮
机构地区 南京医科大学附属淮安第一医院血液科
出处 《白血病．淋巴瘤》 CAS 2014年第6期378-380,共3页 Journal of Leukemia & Lymphoma
基金 国家自然科学基金（81170489） 江苏省自然科学基金（BK2010287） 江苏省卫生厅基金（H201056）
关键词 Bruton酪氨酸激酶 NF-ΚB B细胞肿瘤 Bruton tyrosine kinase NF-κB B cell malignances
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献34

  • 1Tai YT,Chang BY,Kong SY,et al.Bruton's tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma[J].Blood,2012,120:1877-1887.
  • 2Glassford J,Soeiro I,Skarell SM,et al.BCR targets cyclin D2 via Btk and the p85 alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells[J].Oncogene,2003,22:2248-2259.
  • 3Baba Y,Nonoyama S,Matsushita M,et al.Involvement of wiskottaldrich syndrome protein in B-cell cytoplasmic tyrosine kinase pathway[J].Blood,1999,93:2003-2012.
  • 4Crampton SP,Voynova E,Bolland S.Innate pathways to B-cell activation and tolerance[J].Ann N Y Acad Sci,2010,1183:58-68.
  • 5Miller AT,Berg LJ.New insights into the regulation and functions of Tec family tyrosine kinases in the immune system[J].Curr Opin immunol,2002,14:331-340.
  • 6Rickert RC.New insights into pre-BCR and BCR signaling with relevance to B cell malignancies[J].Nat Rev Immunol,2013,13:578-591.
  • 7Baba Y,Hashimoto S,Matsushita M,et al.BLNK mediates Sykdependent Btk activation[J].Proc Natl Acad Sci U S A,2001,98:2582-2586.
  • 8Kabak S,Skaggs BJ,Gold MR,et al.The direct recruitment of BLNK to immunoglobulin alpha couples the B-cell antigen receptor to distal signaling pathways[J].Mol Cell Biol,2002,22:2524-2535.
  • 9Perez de DR,Bravo J,Allende LM,et al.Identification of novel nonpathogenic mutation in SH3 domain of Btk in an XLA patient[J].Mol Immunol,2008,45:301-303.
  • 10Humphries LA,Danqelmaier C,Sommer K,et al.Tec kinases mediate sustained calcium influx via site specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker[J].J Biol Chem,2004,279:37651-37661.

二级参考文献18

  • 1Rosenwald A,Wright G,Chan WC. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma[J].New England Journal of Medicine,2002,(25):1937-1947.doi:10.1056/NEJMoa012914.
  • 2Fisher RI,Gaynor ER,Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin lymphoma[J].New England Journal of Medicine,1993,(14):1002-1006.doi:10.1056/NEJM199304083281404.
  • 3Ohsawa M,Ikura Y,Fukushima H. Immunohistochemical expression of muhidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma[J].Oncology(Basel),2005,(4-6):422-431.
  • 4Jazirehi AR,Huerta-Yepez S,Cheng G. Rituximab(chimeric anti-CD20 monoclonal antibody)inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines:role in sensitization to chemotherapeutic drug-induced apoptosis[J].Cancer Research,2005,(01):264-276.
  • 5Lam LT,Davis RE,Pierce J. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling[J].Clinical Cancer Research,2005,(01):28-40.
  • 6Uddin S,Hussain AR,Siraj AK. Role of phosphatidylinositol3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival[J].Blood,2006,(13):4178-4186.doi:10.1182/blood-2006-04-016907.
  • 7Barancik M,Bohacova V,Sedlak J. LY294002,a specific inhibitor of P13K/Akt kinase pathway,antagonizes P-glycoprotein-mediated multidrug resistance[J].European Journal of Pharmaceutical Sciences,2006,(05):426-434.doi:10.1016/j.ejps.2006.08.006.
  • 8Espinosa I,Bfiones J,Bordes R. Membrane PKC-beta 2protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma[J].Annals of Hematology,2006,(09):597-603.doi:10.1007/s00277-006-0144-y.
  • 9Li S,Phong M,Lahn M. Retrospective analysis of protein kinase C-beta(PKC-beta)expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas[J].Biology Direct,2007,(01):8.doi:10.1186/1745-6150-2-8.
  • 10Kurosu T,Takahashi Y,Fukuda T. p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide[J].Apoptosis:An International Journal on Programmed Cell Death,2005,(05):1111-1120.

共引文献7

同被引文献2

引证文献1

白血病．淋巴瘤
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部